17 Capital Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

17 Capital Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$453K	Buy	1,015 +25	+3%	+$11.7K	0.23%	128
2025 Q4	$449K	Hold	990	–	–	0.23%	124
2025 Q3	$388K	Sell	990 -30	-3%	-$12.5K	0.21%	116
2025 Q2	$454K	Buy	1,020 +20	+2%	+$9.22K	0.26%	101
2025 Q1	$485K	Buy	1,000 +5	+0.5%	+$2.33K	0.31%	97
2024 Q4	$401K	Buy	995 +3	+0.3%	+$1.39K	0.25%	107
2024 Q3	$461K	Buy	992 +2	+0.2%	+$961	0.3%	94
2024 Q2	$464K	Buy	990 +50	+5%	+$21.7K	0.33%	84
2024 Q1	$393K	Sell	940 -985	-51%	-$416K	0.29%	87
2023 Q4	$783K	Buy	+1,925	New	+$711K	0.72%	53
2022 Q3	$431K	Hold	1,490	–	–	0.59%	62
2022 Q2	$420K	Hold	1,490	–	–	0.53%	63
2022 Q1	$389K	Buy	1,490 +350	+31%	+$83.1K	0.41%	72
2021 Q4	$250K	Buy	+1,140	New	+$222K	0.23%	84
2021 Q3	–	Sell	-1,651	Closed	-$333K	–	102
2021 Q2	$333K	Buy	+1,651	New	+$345K	0.31%	85

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

17 Capital Partners's VRTX Position: Q1 2026 in Review

17 Capital Partners increased its Vertex Pharmaceuticals (VRTX) stake by 2.5% in Q1 2026, buying an estimated $11.7K and bringing the position to 1,015 shares worth $453K. The position accounts for 0.23% of the portfolio, ranked #128.

17 Capital Partners first reported a position in VRTX in Q2 2021 and has held it in 15 quarters since. The position peaked at $783K in Q4 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

17 Capital Partners held 1,015 shares of Vertex Pharmaceuticals worth $453K as of Q1 2026.
17 Capital Partners bought 25 Vertex Pharmaceuticals shares in Q1 2026, an estimated $11.7K.
Vertex Pharmaceuticals made up 0.23% of 17 Capital Partners's portfolio in Q1 2026, its #128 holding.
17 Capital Partners first reported a position in Vertex Pharmaceuticals in Q2 2021 and has held it in 15 quarters since.
17 Capital Partners's Vertex Pharmaceuticals position peaked at $783K in Q4 2023.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on 17 Capital Partners's 13F filing for Q1 2026, filed 13 May 2026.